Patient profiles will be assessed to identify those drug regimens, which may result in clinically significant drug-drug interactions. The following drug-drug interactions are considered clinically relevant for immune globulins. Only those drug-drug interactions classified as clinical significance of contraindicated or those considered life-threatening will be reviewed.

Major Interaction : Live/Live Attenuated Virus Vaccines1

  • (e.g., measles, mumps, rubella, varicella, rotavirus)
  • Adjunctive administration of immune globulins with live/live attenuated virus vaccines may inhibit the immune response to the vaccination by passively transferring antibodies and diminishing the desired vaccine effect.
  • It is not recommended to administer varicella-zoster live virus vaccines within 5 months of receiving immunoglobulins, including varicella-zoster immune globulin. After vaccination for varicella, the CDC recommends that immune globulin products should not be administered for 3 weeks unless the benefit outweighs the risk. The manufacturer recommends waiting 2 months before administering immunoglobulins. If immunoglobulin products are administered within 3 weeks of vaccination, then it is recommended to be revaccinated at 5 months or tested for immunity.
  • Rubella or measles/ mumps/ rubella vaccines should not be given for at least 3 months following immunoglobulin administration.
  • Rotavirus vaccines should not be given for at least 3 months following immunoglobulin administration.

Major Interaction: Pozelimab and Ravulizumab1

  • Concomitant use of pozelimab and IVIG may result in reduced clinical efficacy of pozelimab. If use is necessary, it is recommended to monitor for reduced clinical efficacy of pozelimab.
  • Concomitant use of ravulizumab may decrease ravulizumab exposure and efficacy. It is recommended to administer a supplemental dose of ravulizumab and monitor for reduced efficacy in patients on ravulizumab and receiving immune globulin therapy.